Ahmedabad-headquartered Troikaa Pharmaceuticals, which was struggling to get clearances, has begun construction at site in Sanand where it has about 75 acres of land in posession. The company plans to manufacture its novel topical drug delivery system which has been commercialised under the brand name Dynapar QPS, for which it has recently bagged the National Award from Technology Development Board, Department of Science & Technology, Govt of India for successful commercialization of indigenous technology, at Sanand.
Dynapar is a pain relief solution using technology which provides quick and comprehensive penetration of the drug through the skin. The company claims that the drug enables doctors to substantially reduce the dose of oral painkillers and thereby reducing the harmful effects on kidneys, liver and the cardiovascular system. It is useful in treating pain in conditions such as osteoarthritis, rheumatoid arthritis, back pain, pain due to repetitive injury, sprains, sports injuries etc. Ketal Patel,managing director, Troikaa Pharma received the award from the Union minister of science & technology & earth sciences, government of India, Harsh Vardhan.
Earlier, Troikaa's diclofenac injection Dynapar AQ was also given the National Award by Department of Scientific and Industrial Research, Govt of India. The brand is patented in 99 countries, and is considered amongst the largest selling painkiller injection brands in the country.
The company would be investing close to Rs 150 crore in the Sanand facility that will produce the Dyanapar range of drugs. It is also scouting for a partner in the US to enter the market, informed a company spokesperson, adding that it has already appointed a consultant for the same. The company plans to build the Sanand unit as compliant with US FDA norms, and it would be operational by 2017.